Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Chemocentryx Inc.
Headquarters: Mountain View, CA, United States of America
Website: N/A
Year Founded: 1997
Status: Acquired
BioCentury | Feb 23, 2024
Product Development
Amgen sees rare diseases as ‘fourth pillar’ of growth, driven by pair of 2022 deals
The big biotech spotlights pipeline, outlines commercial steps critical for drugs from Horizon, ChemoCentryx takeouts to reach more patients
BioCentury | Oct 25, 2023
Management Tracks
CFO Joanne Bryce to depart Disc
Plus: Jeff Albers joins Scorpion as strategic adviser, and updates from Mironid, 1859, mbiomics and Tevogen
BioCentury | Jan 9, 2023
Deals
CVRs address risks in billion-dollar AZ-CinCor, Ipsen-Albireo deals
Pair of high-premium M&A transactions could deliver shareholders more value tied to regulatory milestones
BioCentury | Dec 24, 2022
BioCentury Commentary
Noisemakers and newsmakers of 2022, and hot takes for 2023
BioCentury’s analysts look back at a year when industry took some slings and arrows but delivered breakthroughs, and predict what’ll be hot in 2023
BioCentury | Dec 12, 2022
Deals
Returning to its roots, Amgen adding growth with $28.7B deal for Horizon
Acquisition bolsters inflammation, autoimmune portfolio after oncology franchise comes under pressure
BioCentury | Nov 1, 2022
Emerging Company Profile
HI-Bio: pairing immune cell-targeting approach with deal to drive clinical work
Backed by Arch, Monograph and Jeito with $120M, the immunology company has jump-started its clinical plan via a deal with MorphoSys
BioCentury | Oct 18, 2022
Deals
Lilly buying otology company Akouos to add another gene therapy pipeline
As biotech nears first-in-human study for genetic hearing loss, pharma deepens commitment to modality via structured deal
BioCentury | Sep 1, 2022
Deals
ChemoCentryx attracted multiple suitors, but not until after first approval
Amgen was one of three companies interested in acquiring ChemoCentryx since April 2020
BioCentury | Aug 9, 2022
Deals
M&A & data: recipe for a rebound?
BioCentury’s latest podcast zeroes in on the deals and data that are rallying biotech indexes
BioCentury | Aug 8, 2022
Product Development
Karuna’s Phase III schizophrenia success primes company for takeout
Results validate CEO Steven Paul’s ‘simple but elegant’ approach to improving xanomeline’s tolerability in schizophrenia patients
Items per page:
1 - 10 of 182